Anaemia is an independent predictor of mortality in patients with left ventricular systolic dysfunction following acute myocardial infarction

European Journal of Heart Failure

Volumn 8, Issue 6, 2006, Pages 577-584

  Valeur, Nana ^a   Nielsen, Olav Wendelboe ^a   McMurray, John J V ^b   Torp Pedersen, Christian ^c   Køber, Lars ^a  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c BISPEBJERG HOSPITAL   (Denmark)

Author keywords

Anaemia; Heart failure; Myocardial infarction; Prognosis

Indexed keywords

ACUTE HEART INFARCTION; ADULT; AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; FEMALE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; RETROSPECTIVE STUDIES; SYSTOLE; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33750029142     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2005.11.017     Document Type: Article

References (23)

1. Androne A.S., Katz S.D., Lund L., et al. Hemodilution is common in patients with advanced heart failure. Circulation 107 2 (2003) 226-229
2. Ezekowitz J.A., McAlister F.A., and Armstrong P.W. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 107 2 (2003) 223-225
3. Felker G.M., Gattis W.A., Leimberger J.D., et al. Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. Am J Cardiol 92 5 (2003) 625-628
4. Horwich T.B., Fonarow G.C., Hamilton M.A., MacLellan W.R., and Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 39 11 (2002) 1780-1786
5. Kalra P.R., Collier T., Cowie M.R., et al. Haemoglobin concentration and prognosis in new cases of heart failure. Lancet 362 9379 (2003) 211-212
6. Kosiborod M., Smith G.L., Radford M.J., Foody J.M., and Krumholz H.M. The prognostic importance of anemia in patients with heart failure. Am J Med 114 2 (2003) 112-119
7. Mancini D.M., Katz S.D., Lang C.C., LaManca J., Hudaihed A., and Androne A.S. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107 2 (2003) 294-299
8. Silverberg D.S., Wexler D., Blum M., Schwartz D., Wollman Y., and Iaina A. Erythropoietin should be part of congestive heart failure management. Kidney Int Suppl 87 (2003) S40-S47
9. Kober L., Torp-Pedersen C., Carlsen J.E., et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction, TRAndolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 333 25 (1995) 1670-1676
10. Kober L., Torp-Pedersen C., Carlsen J., Videbaek R., and Egeblad H. An echocardiographic method for selecting high risk patients shortly after acute myocardial infarction, for inclusion in multi-centre studies (as used in the TRACE study). TRAndolapril Cardiac Evaluation. Eur Heart J 15 12 (1994) 1616-1620
11. Al Falluji N., Lawrence-Nelson J., Kostis J.B., Lacy C.R., Ranjan R., and Wilson A.C. Effect of anemia on 1-year mortality in patients with acute myocardial infarction. Am Heart J 144 4 (2002) 636-641
12. Lipsic E., van dH I., Voors A.A., et al. Hemoglobin levels and 30-day mortality in patients after myocardial infarction. Int J Cardiol 100 2 (2005) 289-292
13. Nikolsky E., Aymong E.D., Halkin A., et al. Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. J Am Coll Cardiol 44 3 (2004) 547-553
14. Sabatine M.S., Morrow D.A., Giugliano R.P., et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 111 16 (2005) 2042-2049
15. Langston R.D., Presley R., Flanders W.D., and McClellan W.M. Renal insufficiency and anemia are independent risk factors for death among patients with acute myocardial infarction. Kidney Int 64 4 (2003) 1398-1405
16. Kalra P.R., Bolger A.P., Francis D.P., et al. Effect of anemia on exercise tolerance in chronic heart failure in men. Am J Cardiol 91 7 (2003) 888-891
17. Silverberg D.S., Wexler D., Sheps D., et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 37 7 (2001) 1775-1780
18. Tepper D. Frontiers in congestive heart failure: anemia is associated with worse symptoms, greater impairment in functional capacity, and a significant increase in mortality in patients with advanced heart failure. Congest Heart Fail 8 4 (2002) 235-236
19. Silverberg D.S., Wexler D., Blum M., et al. The correction of anemia in severe resistant heart failure with erythropoietin and intravenous iron prevents the progression of both the heart and the renal failure and markedly reduces hospitalization. Clin Nephrol 58 Suppl 1 (2002) S37-S45
20. van der Meer P., Voors A.A., Lipsic E., Smilde T.D., van Gilst W.H., and van Veldhuisen D.J. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol 44 1 (2004) 63-67
21. Deswal A., Petersen N.J., Feldman A.M., Young J.B., White B.G., and Mann D.L. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103 16 (2001) 2055-2059
22. Iversen P.O., Woldbaek P.R., Tonnessen T., and Christensen G. Decreased hematopoiesis in bone marrow of mice with congestive heart failure. Am J Physiol Regul Integr Comp Physiol 282 1 (2002) R166-R172
23. Silverberg D.S., Wexler D., Blum M., et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 35 7 (2000) 1737-1744